FDA Requires GLP-1s to Carry Warning About Rare Risk of Vision Loss
The U.S. Food and Drug Administration (FDA) announced this week that it is requiring manufacturers of all GLP-1 diabetes and obesity medications to make labeling changes that will warn patients…